TheraRadar
← Back
Data updated: Nov 8, 2026

WOCKHARDT EU OPERATN

Generics
Infectious DiseaseMetabolicDermatology Execution: Good

WOCKHARDT EU OPERATN is a generic drug manufacturer focused on Infectious Disease, Metabolic, Dermatology.

1999
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

WOCKHARDT EU OPERATN at a Glance

  • Fast trial execution (5 months median completion)

WOCKHARDT EU OPERATN's Key Drugs

WOCKHARDT EU OPERATN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

WOCKHARDT EU OPERATN's Recent FDA Approvals

New NDA/BLA approvals for WOCKHARDT EU OPERATN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

WOCKHARDT EU OPERATN's Therapeutic Areas

WOCKHARDT EU OPERATN's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 47%
0 drugs Phase 3: 3 Phase 2: 2 Phase 1: 2
Metabolic 37%
0 drugs Phase 3: 2 Phase 1: 6
Dermatology 11%
0 drugs Phase 3: 1
Gastroenterology 3%
0 drugs Phase 1: 1
Respiratory 3%
0 drugs Phase 1: 1

WOCKHARDT EU OPERATN's Top Competitors

WOCKHARDT EU OPERATN's closest competitors by therapeutic-area and drug-target overlap include Merck, PHARMACIA AND UPJOHN, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Infectious Disease, Metabolic, Respiratory
PHARMACIA AND UPJOHN big-pharma
Dermatology, Infectious Disease, Respiratory, Metabolic
Johnson & Johnson big-pharma
Infectious Disease, Gastroenterology, Metabolic
GSK big-pharma
Respiratory, Infectious Disease, Metabolic
B BRAUN specialty
Infectious Disease, Dermatology, Metabolic

WOCKHARDT EU OPERATN Pipeline Snapshot

WOCKHARDT EU OPERATN has 18 active clinical programs from ClinicalTrials.gov — 6 Phase 3, 2 Phase 2 and 10 Phase 1.

6
Phase 3
2
Phase 2
10
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/4 completed
  • • Speed: 5 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges